Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?

Shares of Halozyme Therapeutics (HALO) have been strong performers lately, with the stock up 20.6% over the past month. The stock hit a new 52-week high of $74.44 in the previous session. Halozyme Therapeutics has gained 53.4% since the start of the year compared to the -2.1% gain for the Zacks Medical sector and the 3.6% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Cons ...